SCHEMBL6497878

SCHEMBL6497878

O=C(Nc1ccc(C(F)(F)F)cc1)N(CC1CCCN(CCc2ccccc2)C1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.47
CCR2 P41597 3/20 0.47
CCR3 P51677 2/20 0.45
DRD3 P35462 1/20 0.45
UBE2M P61081 2/20 0.45
DCUN1D1 Q96GG9 2/20 0.45
CHRNB2 P17787 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
KCNH2 Q12809 2/20 0.44
MTOR P42345 1/20 0.44
HIF1A Q16665 1/20 0.43
EPAS1 Q99814 1/20 0.43
DNMT1 P26358 1/20 0.42
EHMT2 Q96KQ7 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486577 0.91 CCR2 (0.50) CCR2DRD3CHRNB2CHRNB4CHRNA3
SCHEMBL6500642 0.91 DCUN1D1 (0.55) PKMCCR2UBE2MDCUN1D1KCNH2
SCHEMBL7724270 0.89 ACHE (0.57) CCR2DRD3UBE2MDCUN1D1CHRNB2
SCHEMBL6498997 0.80 LTA4H (0.48) CCR2DRD3CHRNB2CHRNA4KCNH2
SCHEMBL5870761 0.78 OPRM1 (0.50) CCR2DRD3CHRNB2CHRNB4CHRNA3
SCHEMBL5870685 0.77 OPRD1 (0.62) DRD3CHRNA4KCNH2ACHE
SCHEMBL5870682 0.77 OPRD1 (0.62) DRD3CHRNA4KCNH2ACHE
SCHEMBL5870753 0.77 OPRD1 (0.62) DRD3CHRNA4KCNH2ACHE
SCHEMBL5870944 0.76 OPRM1 (0.50)
SCHEMBL5870902 0.75 OPRM1 (0.60) CHRNB2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946477-B2 3-Substituted piperidines comprising urea functionality, and methods of use thereof SEPRACOR INC. (US) 2005-09-20 US disclosed
US-20030114436-A1 3-substituted piperidines comprising urea functionality, and methods of use thereof AQUILA BRIAN M (US) 2003-06-19 US disclosed
US-6476050-B2 ANALGESICS; LIGANDS FOR VARIOUS CELLULAR RECEPTORS, INCLUDING OPIOID RECEPTORS, OTHER G-PROTEIN-COUPLED RECEPTORS AND ION CHANNELS SEPRACOR, INC. 2002-11-05 US disclosed
US-20010056090-A1 3-substituted piperidines comprising urea functionality, and methods of use thereof SEPRACOR INC. 2001-12-27 US disclosed
WO-2001068604-A2 3-SUBSTITUTED PIPERIDINES COMPRISING UREA FUNCTIONALITY, AND METHODS OF USE THEREOF SEPRACOR, INC. (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056090-A1 3-substituted piperidines comprising urea functionality, and methods of use thereof OPRM1, OPRL1, OPRK1 PKM 2468/4885CCR2 692/4885CCR3 915/4885
US-20030114436-A1 3-substituted piperidines comprising urea functionality, and methods of use thereof OPRM1, OPRL1, OPRK1 PKM 2468/4885CCR2 692/4885CCR3 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.